Evidence map›Paper›PMID 23400978›Full record

ArticleAnesthesia and analgesia2013

The pyrrole etomidate analog carboetomidate potently inhibits human 5-HT3A receptor function: comparisons with etomidate and potential implications for emetogenesis.

Rooma Desai, Keith W Miller, Douglas E Raines

Open access · greenAbstract readComparative Study
In one paragraph

Article in Anesthesia and analgesia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. A mild and efficient AgSbFTetrahedron · 2014
    Article
  3. Etomidate derivatives: Novel pharmaceutical agents in anesthesia.Journal of anaesthesiology, clinical pharmacology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rooma DesaiDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114-2621, USA.
Keith W Miller
Douglas E Raines
Massachusetts General Hospital · US

Funding

Synthetic Chemistry CoreP01GM058448 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KEITH W · 1999 to 2018
$33.6M
Etomidate Analogues as Safer General AnestheticsR01GM087316 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI RAINES, DOUGLAS E · 2010 to 2016
$3.2M
Preclinical Studies of Carbo-etomidate: An Etomidate Analogue for Use in SepsisR21DA029253 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI RAINES, DOUGLAS E · 2010 to 2011
$475k
NIDA NIH HHS R21 DA029253NIDA NIH HHS R21-DA029253NIGMS NIH HHS 2P01-GM058448-11NIGMS NIH HHS P01 GM058448NIGMS NIH HHS R01 GM087316NIGMS NIH HHS R01-GM087316
6 · The paper itself

Abstract

background5-Hydroxytryptamine type 3 (5-HT(3)) receptors are excitatory ion channels belonging to the cys-loop family of ligand-gated ion channels. They are involved in nausea and vomiting and their antagonists are used clinically as antiemetic drugs. We previously reported the development of a novel pyrrole analog of etomidate, (R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate), which retains etomidate's desirable anesthetic and hemodynamic properties, but lacks its potent inhibitory effect on adrenocorticotropic hormone-stimulated steroid synthesis. Also in contrast to etomidate, carboetomidate potently inhibits nicotinic acetylcholine receptors. Because nicotinic acetylcholine and 5-HT(3) receptors are highly homologous, we hypothesized that carboetomidate might also potently inhibit 5-HT(3) receptors with potentially important implications for the drug's emetogenic activity. In the current studies, we investigated and compared modulation of 5-HT(3A) receptors by carboetomidate and etomidate.

methods5-HT(3) receptors were heterologously expressed in human embryonic kidney cells. Drugs were applied with a multichannel superfusion pipette coupled to piezoelectric elements, and currents were recorded from cells in either the whole-cell or excised outside-out patch configuration of patch-clamp recordings.

resultsCarboetomidate and etomidate inhibited integrated 5-HT(3A) receptor-mediated currents with respective half-inhibitory concentrations of 1.9 μM (95% confidence interval [CI] = 1.4-2.7 μM) and 25 μM (95% CI = 17-37 μM). These values may be compared with respective hypnotic concentrations of 5.4 and 2.3 µM. This inhibition reflected hypnotic effects on peak current amplitudes and desensitization rates. Half-inhibitory concentrations for reducing peak current amplitudes were 34 μM (95% CI = 24-48 µM) for carboetomidate and 171 μM (95% CI = 128-228 µM) for etomidate. Half-inhibitory concentrations for reducing the desensitization time constant were 3.5 μM (95% CI = 2.4-5.1 µM) for carboetomidate and 36 μM (95% CI = 21-59 µM) for etomidate.

conclusionsIn contrast to etomidate, carboetomidate inhibits 5-HT(3A) receptor-mediated currents at hypnotic concentrations. This inhibition is primarily the result of enhancing the rate of desensitization. Because carboetomidate potently inhibits 5-HT(3A) receptors, it may be less emetogenic than etomidate.

Indexed as

EtomidateHEK293 CellsHumansHypnotics and SedativesPyrrolesReceptors, Serotonin, 5-HT3Serotonin 5-HT3 Receptor AntagonistscarboetomidateEtomidateHypnotics and SedativesPyrrolesReceptors, Serotonin, 5-HT3Serotonin 5-HT3 Receptor Antagonists

Identifiers

PMID23400978
PMCPMC3582768
OpenAlexW2024439236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.